To report the FDA approval of remibrutinib for adults with symptomatic dermographism inadequately controlled with H1 antihistamines and summarize the supporting RemIND trial findings.
Approach:
Approval: The FDA approved oral remibrutinib (Rhapsido), a Bruton tyrosine kinase inhibitor, for adults with symptomatic dermographism whose symptoms remain inadequately controlled with H1 antihistamines.
Evidence: Approval was supported by the symptomatic dermographism cohort of the phase 3 RemIND trial, which compared remibrutinib with placebo in patients symptomatic despite second-generation H1 antihistamines.
Key Findings:
At week 12, complete hive response, assessed using the Total Fric Score, occurred in 29.3% of patients receiving remibrutinib and 14.0% receiving placebo.
Novartis reported responses as early as week 2.
Through week 24, adverse events occurring in at least 3% of patients included nasopharyngitis, bleeding, headache, nausea, and abdominal pain.
The safety profile was reported as consistent with that in chronic spontaneous urticaria; routine laboratory monitoring is not required.
Interpretation:
The approval makes remibrutinib the first FDA-approved treatment for symptomatic dermographism. In the United States, it is also approved for chronic spontaneous urticaria when symptoms are inadequately controlled with H1 antihistamines.
Limitations:
The provided context does not report the trial cohort size, confidence intervals, or statistical significance for the response comparison.
The safety and efficacy details provided are limited to the reported outcomes through week 24.
Conclusion:
RemIND also evaluated remibrutinib in cold and cholinergic urticaria. Novartis said it plans to submit the full trial dataset to health authorities globally where appropriate; the drug remains under study in hidradenitis suppurativa, food allergy, and multiple sclerosis.
